Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences
September 05 2017 - 8:00AM
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage
biopharmaceutical company developing novel antibiotics to treat
life-threatening multidrug-resistant (MDR) infections, today
announced that company management will present at the following
upcoming investor conferences:
- Rodman & Renshaw 19th Annual Global Investment Conference
on Monday, September 11th, 2017 at 12:30 p.m. Eastern Time at the
Lotte New York Palace Hotel in New York City
- Cantor Fitzgerald Global Healthcare Conference on Monday,
September 25th at 1:50 p.m. Eastern Time at the InterContinental
New York Barclay Hotel in New York City
Live audio webcasts of the presentations will be
available on the company’s website at
http://ir.tphase.com/events.cfm. Archived presentations will be
available for 30 days.
About Tetraphase Pharmaceuticals,
Inc.Tetraphase is a clinical-stage biopharmaceutical
company using its proprietary chemistry technology to create novel
antibiotics for serious and life-threatening bacterial infections,
including those caused by many of the multidrug-resistant (MDR)
bacteria highlighted as urgent public health threats by the CDC.
Tetraphase has created more than 3,000 novel tetracycline analogs
using its proprietary technology platform. Tetraphase's pipeline
includes three antibiotic clinical candidates: eravacycline, which
is in phase 3 clinical trials, and TP-271 and TP-6076, which are in
phase 1 clinical trials. Please visit www.tphase.com for more
company information.
Investor Contacts:
Tetraphase Pharmaceuticals
Teri Dahlman
617-600-7040
tdahlman@tphase.com
Argot Partners
Maeve Conneighton
206-899-4940
maeve@argotpartners.com
Media Contact:
Sam Brown Inc.
Mike Beyer
312-961-2502
mikebeyer@sambrown.com
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Sep 2023 to Sep 2024